Boston Scientific Corp (NYSE: BSX) is a medical device company that develops, manufactures, and sells devices used in minimally invasive medical procedures across cardiology, electrophysiology, endoscopy, urology, and neuromodulation. Revenue is transactional, generated through direct sales of single-use and implantable devices to hospitals, clinics, and physicians. BSX reported net sales of $16,747M in FY2024, up 17.6% year-over-year, and net sales operational growth of 19.2% in FY2025. Organic growth was 15.8% in FY2025 and 16.4% in FY2024, with the Electrophysiology business unit cited as a primary growth driver in both periods. The company does not pay a cash dividend and made no share repurchases in FY2024 or FY2025, retaining the full $1.000B authorization from the 2020 Share Repurchase Program as of December 31, 2025. Headquarters are in Marlborough, Massachusetts. Current leadership and founding details are not supported by the provided filing excerpts.

Revenue model

Transactional sales of medical devices, including single-use consumables and implantable products, sold directly to hospitals, clinics, and physicians. No subscription or recurring-fee model is disclosed in the excerpts.

Products and services

Medical devices for minimally invasive procedures across electrophysiology, cardiology, endoscopy, urology, and neuromodulation. The Electrophysiology business unit was the primary growth driver in FY2024 and FY2025 per the 10-K filed 2026-02-17.

Customers and end markets

Hospitals, clinics, and physicians. End markets include cardiac rhythm management, electrophysiology, endoscopy, urology, and neuromodulation. No customer concentration data is disclosed in the provided excerpts.

Value-chain role

Medical device manufacturer and direct commercial seller. Develops and manufactures devices internally, then sells through its own commercial organization to healthcare providers.

Geographic exposure

Global operations with foreign currency fluctuations cited as a factor, reducing reported growth by 0.7 percentage points in FY2025. Specific regional revenue breakdown is not supported by the provided excerpts.

Source: SEC 10-K, filed 2026-02-17

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories Baxter International Inc Becton Dickinson and Co Edwards Lifesciences Corp Dexcom Inc IDEXX Laboratories Inc Intuitive Surgical Inc Resmed Inc Stryker Corp